Abeona Therapeutics Inc. | Ownership
Companies that own Abeona Therapeutics Inc.
Fidelity Management & Research Co.
6,916,307
14.43%
2,183,016
0.01%
06/30/2018
T. Rowe Price Associates, Inc.
3,749,607
7.82%
2,413,427
0.01%
06/30/2018
SSgA Funds Management, Inc.
3,059,383
6.38%
650,722
0%
06/30/2018
Viking Global Investors LP
2,550,741
5.32%
-677,967
0.2%
06/30/2018
Wellington Management Co. LLP
2,512,909
5.24%
398,254
0.01%
06/30/2018
Knoll Capital Management LP
2,359,767
4.92%
0
31.64%
06/30/2018
Adage Capital Management LP
2,250,000
4.69%
-63,959
0.08%
06/30/2018
Baker Bros. Advisors LP
2,184,364
4.55%
0
0.22%
06/30/2018
BlackRock Fund Advisors
2,014,112
4.2%
291,533
0%
06/30/2018
The Vanguard Group, Inc.
1,371,998
2.86%
22,563
0%
06/30/2018
| Address |
1330 Avenue of the Americas
New York New York 10019
United States
|
|
Employees
|
- |
| Website |
http://www.abeonatherapeutics.com |
| Updated |
07/08/2019 |
| Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Dallas, TX. |
